CEO Ben Bergo (Visus)
No more squinting at menus? Visus Therapeutics nabs $36M for presbyopia-correcting eye drop
Visus Therapeutics is off to a bit of a late start in the race for a therapeutic alternative to reading glasses. But with an added …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
